Ingeborg Tinhofer

List of Publications by Citations

30 papers	394 citations	10 h-index	19 g-index
30 ext. papers	548 ext. citations	5.7 avg, IF	3.96 L-index

#	Paper	IF	Citations
30	Novel prognostic clinical factors and biomarkers for outcome prediction in head and neck cancer: a systematic review. *Lancet Oncology, The*, **2019**, 20, e313-e326	21.7	67
29	Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. *Oncotarget*, **2016**, 7, 85349-85364	3.3	63
28	Patient and treatment-related risk factors for osteoradionecrosis of the jaw in patients with head and neck cancer. *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*, **2016**, 121, 215-21.e1	2	49
27	MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. *European Journal of Cancer*, **2017**, 77, 3-12	7.5	34
26	Multilayered Omics-Based Analysis of a Head and Neck Cancer Model of Cisplatin Resistance Reveals Intratumoral Heterogeneity and Treatment-Induced Clonal Selection. *Clinical Cancer Research*, **2018**, 24, 158-168	12.9	33
25	Mutational load and mutational patterns in relation to age in head and neck cancer. *Oncotarget*, **2016**, 7, 69188-69199	3.3	20
24	Spheroid Culture of Head and Neck Cancer Cells Reveals an Important Role of EGFR Signalling in Anchorage Independent Survival. *PLoS ONE*, **2016**, 11, e0163149	3.7	19
23	Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer. *International Journal of Cancer*, **2017**, 141, 1215-1221	7.5	17
22	CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab. *Journal of Translational Medicine*, **2015**, 13, 106	8.5	11
21	Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer. *Oncotarget*, **2020**, 11, 3688-3697	3.3	10
20	A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation. *Scientific Reports*, **2020**, 10, 17671	4.9	10
19	Next-generation sequencing: hype and hope for development of personalized radiation therapy?. *Radiation Oncology*, **2015**, 10, 183	4.2	8
18	68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer. *PLoS ONE*, **2020**, 15, e0240892	3.7	7
17	The role of Next-Generation Sequencing in tumoral radiosensitivity prediction. *Clinical and Translational Radiation Oncology*, **2017**, 3, 16-20	4.6	6
16	Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer. *Cancer Immunology, Immunotherapy*, **2019**, 68, 1443-1454	7.4	6
15	Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade. *PLoS ONE*, **2014**, 9, e98867	3.7	6
14	Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies. *Cancers of the Head & Neck*, **2020**, 5, 9	5.9	6

13	The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer. *Cancers of the Head & Neck*, **2016**, 1, 8	5.9	6
12	Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC. *International Journal of Cancer* , **2020**, 147, 2293-2302	7.5	5
11	Fever range whole body hyperthermia for re-irradiation of head and neck squamous cell carcinomas: Final results of a prospective study. *Oral Oncology*, **2021**, 116, 105240	4.4	4
10	Establishment and Validation of CyberKnife Irradiation in a Syngeneic Glioblastoma Mouse Model. *Cancers*, **2021**, 13,	6.6	3
9	PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study. *F1000Research*, **2020**, 9, 1350	3.6	2
8	Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. *Journal of Molecular Diagnostics*, **2020**, 22, 801-810	5.1	1
7	Prognostic Factors Predict Oncological Outcome in Older Patients With Head and Neck Cancer Undergoing Chemoradiation Treatment. *Frontiers in Oncology*, **2020**, 10, 566318	5.3	1
6	Pilot investigation on the dose-dependent impact of irradiation on primary human alveolar osteoblasts in vitro. *Scientific Reports*, **2021**, 11, 19833	4.9	0
5	Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy. *International Journal of Cancer*, **2021**, 150, 603	7.5	
4	68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer **2020**, 15, e0240892		
3	68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer **2020**, 15, e0240892		
2	68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer **2020**, 15, e0240892		
1	68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer **2020**, 15, e0240892		